A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.
Respiratory syncytial virus (RSV) is an important cause of respiratory infection in people of all ages, and is the leading cause of hospitalization in infants. Although commercially available monoclonal antibody is available for passive prophylaxis of neonates at risk of severe disease, there is no available vaccine to prevent RSV. Measurement of neutralizing activity will be a key endpoint for vaccine evaluation. Assessment of neutralizing antibody against RSV has been limited to traditional plaque reduction, which is time-consuming and inherently operator dependent and highly variable. Here, we describe a flow cytometry-based RSV-specific neutralization assay which is more rapid than traditional methods, highly sensitive and highly reproducible.
Chen
M
M
Viral Pathogenesis Laboratory and Clinical Trials Core, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, 40 Convent Drive, Bethesda, MD 20892, United States.
Chang
J S
JS
Nason
M
M
Rangel
D
D
Gall
J G
JG
Graham
B S
BS
Ledgerwood
J E
JE
D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D002460:Cell Line; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018357:Respiratory Syncytial Virus Infections / Q000097:blood* / Q000517:prevention & control; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000276:immunology; D012136:Respiratory Syncytial Viruses; D012680:Sensitivity and Specificity
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D022261:Respiratory Syncytial Virus Vaccines